78 results about "Gpr119 agonist" patented technology

Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.

Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.

Use of oxymethylene aryl GPR119 agonists and DPP IV inhibitors for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control are provided.

The present invention discloses a GPR119 agonist, with a structural formula shown in a general formula (I). The present invention also provides methods for treating diseases with GPR119 as a treatment target, by administration of any pharmaceutically acceptable compound shown in the general formula (I), and the pharmaceutically acceptable salt of the compound; and method for treating or preventing metabolic disorders and obesity by administration of any pharmaceutically acceptable compound shown in the general formula (I), and the pharmaceutically acceptable salt of the compound.

The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

The present invention relates to the GPR119 agonist, 1-methylcyclopropyl 4-(5-fluoro-6-(2-methyl-6-(methylsulfonyl)pyridin-3-yloxy)pyrimidin-4-yloxy)piperidine-1-carboxylate (Compound 1): and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as single pharmaceutical agents or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing the secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.

The present invention is directed to therapeutic compounds of the following formula (I)

Substituted piperidinyl compounds of the formula (I): are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.

The invention relates to the field of medicines related to type 2 diabetes, and in particular relates to a GPR119 agonist containing a hydrazide structure, and a preparation method and application thereof in preparation of a medicine for treating type 2 diabetes. The GPR119 agonist disclosed by the invention is represented by the formula shown in the specification, wherein R is selected from a group including H, C1-C3 alkyl and C3-C6 cycloalkyl.

The invention provides a pyrimidopyrimidine type derivative as well as a preparation method and application thereof to medicines. The invention relates to a novel pyrimidopyrimidine type derivative shown as a general formula I, a preparation method thereof and application of a pharmaceutical composition containing the derivative and pharmaceutically acceptable salt, which are used as a treatment agent, especially a GPR119 agonist, and to medicines for treating anti-diabetic and metabolic diseases and preventing diseases including metabolism disorder and obesity.

The invention provides a quinolinone derivative as shown in a general formula I and a preparation method thereof, wherein R indicates C1-C4 alkyl. The invention also provides application of the quinolinone derivative as a GPR119 excitant and in preparing a drug for treating diabetes. The compound provided by the invention has certain biological activity and most importantly, the compound provided by the invention is a novel GPR119 excitant with good physicochemical properties.

The invention relates to the field of medicines related to type II diabetes mellitus and in particular relates to a GPR119 agonist containing cyclopropyl hydrazide and halogenated benzene structures, a preparation method of the GPR119 agonist and application of the GPR119 agonist to preparation of medicines related to type II diabetes mellitus. The GPR119 agonist has a structure shown in a general formula in the specification, wherein in the general formula, X is selected from halogen substituent.

The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R¹ are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

The invention relates to the field of medicines related to type II diabetes mellitus and in particular relates to a GPR119 agonist containing an alkyl substituted benzenesulfonyl hydrazine structure, a preparation method of the GPR119 agonist and application of the GPR119 agonist to preparation of medicines related to type II diabetes mellitus. The GPR119 agonist has a structure shown in a general formula in the specification, wherein in the general formula, R is selected from C1-C3 alkyl.

The invention relates to the field of drugs associated with Type II diabetes and particularly relates to a GPR119 agonist containing glucosamine and a nitrile pyridine structure shown in the specification as well as a preparation method thereof and an application of the GPR119 agonist in preparation of Type II diabetes drugs.